Virtuoso Surgical has received FDA approval via the de novo pathway for its robotic system dedicated to endoscopic surgeries for bladder tumor resection. This system represents a new class of electromechanical surgical systems designed for intracavitary procedures, where tools are inserted via an endoscope.
Mechanism of Action and Technical Innovation
The system relies on two miniature robotic arms mounted at the tip of a standard endoscope, allowing surgeons to operate through the urethra without the need for any surgical incisions. The technical value of the system lies in its ability to perform en bloc resection, a process of removing the tumor as a single piece or in large segments, rather than the traditional method that relies on fragmenting the tumor into small pieces.
Why Does This News Matter?
Diagnostic accuracy and cancer staging are vital in the treatment of bladder tumors. Fragmenting the tumor using traditional methods leads to tissue damage, making it difficult for pathologists to accurately assess the condition. By preserving the integrity of the tumor, the Virtuoso system provides higher quality tissue samples, which supports more precise treatment plans.
Results from the VIABLE study conducted at the Chinese University of Hong Kong demonstrated high efficacy for the system; the detrusor muscle—which is essential for cancer staging—was found in 94% of the resected samples, surpassing the traditional rate of approximately 70%, with no adverse events recorded during surgery.
Availability and Future Plans
The company is scheduled to begin a centralized launch of the system in the United States during 2027, focusing on leading urology centers. The company plans to explore the possibility of expanding the platform's use to include other surgical specialties that use rigid endoscopes, having already completed preliminary trials in the fields of gynecology, lung procedures, and neurosurgery.